DB18987InvestigationalProtein Based Therapies
Tobemstomig is under investigation in clinical trial NCT05908786 (A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma).
- Mechanism
- Curator reviewed
Pharmacologically active on Programmed cell death protein 1 and Lymphocyte activation gene 3 protein
- Code names
- RO-7247669
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Tobemstomig, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account